Comparative Pharmacology
Head-to-head clinical analysis: HEPARIN SODIUM 5 000 UNITS IN SODIUM CHLORIDE 0 9 versus MAGNESIUM SULFATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HEPARIN SODIUM 5 000 UNITS IN SODIUM CHLORIDE 0 9 versus MAGNESIUM SULFATE.
HEPARIN SODIUM 5,000 UNITS IN SODIUM CHLORIDE 0.9% vs MAGNESIUM SULFATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Heparin binds to antithrombin III, accelerating its inactivation of thrombin (factor IIa) and factor Xa, thereby inhibiting coagulation.
Magnesium sulfate acts as a physiological calcium channel blocker. It inhibits calcium influx into presynaptic nerve terminals, reducing acetylcholine release at the neuromuscular junction and decreasing muscle contraction. It also antagonizes NMDA receptors and stabilizes neuronal membranes.
5,000 units IV bolus, followed by continuous IV infusion of 18 units/kg/hr (initial based on actual body weight) for treatment of venous thromboembolism; or 5,000 units subcutaneously every 8-12 hours for prophylaxis of deep vein thrombosis. Titrate to aPTT 1.5-2.5 times control.
IV: Loading dose 4-6 g over 20-30 minutes, followed by maintenance infusion 1-2 g/hour for seizure prophylaxis in severe preeclampsia/eclampsia. IM: 4-8 g deep IM initially, then 4 g every 4 hours as needed.
None Documented
None Documented
Terminal half-life: 1-2 hours (dose-dependent; mean 1.5 hours). Clinical context: Prolonged in hepatic/renal insufficiency; obesity (increased Vd). IV bolus: 30-60 min; continuous infusion: 1-2 hours.
Terminal elimination half-life approximately 4-6 hours in patients with normal renal function; prolonged to 12-24 hours or more in renal impairment, necessitating dose adjustment
Renal: 40% as unchanged drug; reticuloendothelial system (liver, spleen): 60% metabolized to low molecular weight forms, then renally eliminated.
Primarily renal (90-95% as unchanged drug); minor biliary/fecal (<5%)
Category A/B
Category C
Electrolyte
Electrolyte